Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects

Clinical Therapeutics

Volumn 29, Issue 8, 2007, Pages 1692-1705

  O'Farrell, A Marie ^a   van Vliet, Andre ^b   Abou Farha, Khalid ^b   Cherrington, Julie M ^a   Campbell, David A ^a   Li, Xinqiang ^a   Hanway, Denise ^a   Li, Jianke ^a   Guler, Hans Peter ^a  

^a Phenomix Corporation   (United States)

^b PRA Health Sciences   (Netherlands)

Author keywords

antihyperglycemic; dipeptidyl peptidase 4 inhibitor; DPP4; PHX1149; type 2 diabetes mellitus

Indexed keywords

DECAPENTAPLEGIC PROTEIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; PHX 1149; PLACEBO; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ADULT; AREA UNDER THE CURVE; ARTICLE; BACKACHE; BLOOD LEVEL; BLOOD SAMPLING; CALIBRATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG INDUCED HEADACHE; DRUG TOLERANCE; ELECTROCARDIOGRAPHY; ERUCTATION; FEMALE; FLATULENCE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; INTESTINE MOTILITY; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MONITORING; MYALGIA; NAUSEA; NORMAL HUMAN; POLYURIA; RANDOMIZED CONTROLLED TRIAL; REVERSED PHASE LIQUID CHROMATOGRAPHY; RHINOPHARYNGITIS; SEDATION; SIDE EFFECT; SINGLE DRUG DOSE; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS; VITAL SIGN;

ADMINISTRATION, ORAL; ADULT; ANTIGENS, CD26; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HALF-LIFE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; PROTEASE INHIBITORS; REFERENCE VALUES;

EID: 34848834456     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2007.08.005     Document Type: Article

References (28)

1. Demuth H., Mclntosh C., and Pederson R. Type 2 diabetes-Therapy with dipeptidyl peptidase IV inhibitors. Biochem Biophys Acta 1751 (2005) 33-44
2. Hoist J., and Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab 287 (2004) E199-E206
3. Drucker D. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 26 (2003) 2929-2940
4. Byetta (amylin) exenatide injection [product information] [PDR Electronic Library]. Available at: http://www.thomsonhc.com. Accessed July 27, 2007.
5. Riddle M., and Drucker D. Emerging therapies mimicking the effects of amylin and glucagon-like peptide 1. Diabetes Care 29 (2006) 435-449
6. De Leon D., Crutchlow M., Ham J., and Stoffers D. Role of glucagon-like peptide-1 in the pathogenesis and treatment of diabetes mellitus. Int J Biochem Cell Biol 38 (2006) 845-859
7. Mitani H., Takimoto M., Hughes T., and Kimura M. Dipeptidyl peptidase IV inhibition improves impaired glucose tolerance in high-fat diet-fed rats: Study using a Fischer 344 rat substrain deficient in its enzyme activity. Jpn J Pharmacol 88 (2002) 442-450
8. Conarello S., Li Z., Ronan J., et al. Mice lacking dipeptidyl peptidase IV are protected against obesity and insulin resistance. Proc Nail Acad Sci USA 100 (2003) 6825-6830
9. Marguet D., Baggio L., Kobayashi T., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci U.S.A 97 (2000) 6874-6879
10. Weber A. Dipeptidyl peptidase IV inhibitors for the treatment of diabetes. J Med Chem 47 (2004) 4135-4141
11. Nielsen L. Incretin mimetics and DPP-IV inhibitors for the treatment of type 2 diabetes. Drug Discov Today 10 (2005) 703-710
12. Kim D., Wang L., Beconi M., et al. (2 R)-4-oxo-4-[3-(trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-l-(2,4,S-trifluorophenyl)butan-2-amine: Apotent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 141-151
13. Hansotia T., and Drucker D. GIP and GLP-1 as incretin hormones: Lessons from single and double incretin receptor knockout mice. Regul Pept 128 (2005) 125-134
14. Pospisilik J., Stafford S., Demuth H., et al. Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51 (2002) 943-950
15. Ahren B., Gomis R., Standl E., et al. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
16. Raz I., Hanefeld M., Xu L., et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
17. Ahren B., Landin-Olsson M., Jansson P., et al. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
18. Barnett A. DPP4 inhibitors and their potential role in the management of type 2 diabetes. Int J Clin Pract 60 (2006) 1454-1470
19. Li X., Winn D., O'Farrell A.-M., et al. Preclinical development of PHX1149, an orally available, potent and selective DPP4 (dipeptidyl peptidase) inhibitor. Diabetes 55 (2006) A128 Abstract 538-P
20. World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects [WMA Web site]. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland, October 2000. Available at: http://www.wma.net/e/policy/b3.htm. Accessed July 26, 2007.
21. European Agency for the Evaluation of Medicinal Products. Guideline for Good Clinical Practice [EMEA Web site]. ICH Topic E6. Geneva, Switzerland. International Conference on Harmonisation- World Health Organization. WHO (2002). http://www.emea.eu.int Available at:
22. PHX1149 rat validation (2006), Phenomix Corporation, San Diego, Calif
23. Validation human plasma final (2006), Phenomix Corporation, San Diego, Calif Study no. 3609
24. Validation-BiodppIV (2006), Phenomix Corporation, San Diego, Calif Study no. 5101
25. US Food and Drug Administration. Medical Dictionary for Regulatory Activities [MedDRA Web site]. Available at: http://www.meddramsso.com/MSSOWeb/index.htm. Accessed July 26, 2007.
26. Herman G., Bergman A., Stevens C., et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels following an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 91 (2006) 4612-4619
27. Herman G., Bergman A., Liu F., et al. Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects. J Clin Pharmacol 46 (2006) 876-886
28. Bergman A., Stevens C., Zhou Y., et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses ofsitagliptin, a dipeptidyl peptidase-IV inhibitor: A double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28 (2006) 55-72